We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.01%
This Fund
S&P 500
This Quarter
Est. Return
+6.89%
1 Year Est. Return
+62.01%
3 Year Est. Return
+164.15%
5 Year Est. Return
+274.12%
10 Year Est. Return
+2,470.02%
AUM
$1.31B
AUM Growth
-$51.4M
(-3.8%)
Cap. Flow
-$54.7M
Cap. Flow
% of AUM
-4.18%
Top 10 Holdings %
Top 10 Hldgs %
12.11%
Holding
1,682
New
422
Increased
338
Reduced
347
Closed
506
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Penumbra
PEN
|
+$15.3M |
| 2 |
Meta Platforms (Facebook)
META
|
+$13.5M |
| 3 |
CWAN
Clearwater Analytics
CWAN
|
+$13M |
| 4 |
Appian
APPN
|
+$10.6M |
| 5 |
VSNT
Versant Media Group
VSNT
|
+$9.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SPDR Gold Trust
GLD
|
+$18.2M |
| 2 |
Teradyne
TER
|
+$15.9M |
| 3 |
Bloom Energy
BE
|
+$15.3M |
| 4 |
CYBR
CyberArk
CYBR
|
+$15.2M |
| 5 |
EXAS
Exact Sciences
EXAS
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.29% |
| 2 | Healthcare | 14.62% |
| 3 | Consumer Discretionary | 10.89% |
| 4 | Industrials | 8.81% |
| 5 | Communication Services | 8.36% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1126
Larimar Therapeutics
LRMR
$397M
| $48.9K | ﹤0.01% |
10,867
| – | – |
|
1127
8x8 Inc
EGHT
$269M
| $48.7K | ﹤0.01% |
29,365
-1,000
| -3% | -$2.05K |
|
1128
Zentalis Pharmaceuticals
ZNTL
$337M
| $47.7K | ﹤0.01% |
+20,400
| New | +$52.7K |
|
1129
Soluna Holdings
SLNH
$192M
| $47.6K | ﹤0.01% |
67,413
-11,904
| -15% | -$12.7K |
|
|
GRCE
1130
Grace Therapeutics
GRCE
$33.8M
| $46.6K | ﹤0.01% |
+10,074
| New | +$39.6K |
|
1131
Tigo Energy
TYGO
$145M
| $46.2K | ﹤0.01% |
+12,294
| New | +$40.7K |
|
|
GRO
1132
Brazil Potash Corp
GRO
$125M
| $45.9K | ﹤0.01% |
+14,157
| New | +$40.1K |
|
1133
E.W. Scripps
SSP
$257M
| $43.6K | ﹤0.01% |
+11,728
| New | +$43.3K |
|
|
ESPR
1134
DELISTED
Esperion Therapeutics
ESPR
| $42.9K | ﹤0.01% |
15,670
-11,388
| -42% | -$36.1K |
|
1135
Telos
TLS
$332M
| $42.7K | ﹤0.01% |
+10,200
| New | +$48.2K |
|
1136
Invivyd
IVVD
$158M
| $41.8K | ﹤0.01% |
+32,163
| New | +$59.1K |
|
1137
Protalix BioTherapeutics
PLX
$191M
| $41K | ﹤0.01% |
18,900
-3,343
| -15% | -$8.3K |
|
1138
Nephros
NEPH
$36.8M
| $40.8K | ﹤0.01% |
13,680
-1,500
| -10% | -$5.99K |
|
1139
Yatra Online
YTRA
$52.7M
| $40.7K | ﹤0.01% |
36,698
-1,900
| -5% | -$2.64K |
|
|
VIOT
1140
Viomi Technology
VIOT
$51.8M
| $37.9K | ﹤0.01% |
+34,175
| New | +$47.5K |
|
|
AUTL
1141
Autolus Therapeutics
AUTL
$397M
| $37.5K | ﹤0.01% |
27,200
-4,808
| -15% | -$7.3K |
|
|
FNUC
1142
Frontier Nuclear and Minerals Inc
FNUC
$40.5M
| $37.3K | ﹤0.01% |
+13,277
| New | +$40.1K |
|
1143
Energy Vault
NRGV
$517M
| $35.9K | ﹤0.01% |
+10,875
| New | +$44.9K |
|
|
WHWK
1144
Whitehawk Therapeutics
WHWK
$190M
| $35.5K | ﹤0.01% |
10,283
-8,513
| -45% | -$26.7K |
|
1145
Acrivon Therapeutics
ACRV
$64.2M
| $33.4K | ﹤0.01% |
24,015
-24,000
| -50% | -$41.9K |
|
1146
Organogenesis Holdings
ORGO
$305M
| $33.2K | ﹤0.01% |
+14,008
| New | +$48.5K |
|
|
CIRC
1147
Circle8 Group
CIRC
$64.5M
| $32.9K | ﹤0.01% |
+10,852
| New | +$34.3K |
|
1148
CuriosityStream
CURI
$145M
| $32.7K | ﹤0.01% |
11,055
-28,900
| -72% | -$97.6K |
|
1149
Entravision Communication
EVC
$1.03B
| $32.7K | ﹤0.01% |
+11,000
| New | +$33.7K |
|
1150
Recursion Pharmaceuticals
RXRX
$1.59B
| $30.7K | ﹤0.01% |
10,000
| – | – |
|
Similar funds
QCM
PFBT
CCP
SP
WGAM
HCS
B
SPC
Prelude Capital Management's Q1 2026 Portfolio in Review
As of Q1 2026, Prelude Capital Management held 1,682 positions worth $1.31B, down 3.8% from $1.36B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Prelude Capital Management withdrew a net $54.7M in Q1 2026, closing 506 positions and reducing 347 holdings. Its most notable exit was CyberArk, an estimated $15.2M position sold in full.
By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, Prelude Capital Management opened a new position in Appian worth $9.41M.
- Prelude Capital Management's largest Q1 2026 buy was Appian: 390,321 shares worth $9.41M.
- Prelude Capital Management added most to Penumbra in Q1 2026, an estimated $15.3M increase.
- Prelude Capital Management's biggest Q1 2026 reduction was SPDR Gold Trust, cutting an estimated $18.2M.
- Prelude Capital Management fully exited CyberArk in Q1 2026, selling an estimated $15.2M.
- Prelude Capital Management's ten largest holdings make up 12% of its $1.31B portfolio in Q1 2026.
- Prelude Capital Management opened 422 new positions and closed 506 in Q1 2026.
- Prelude Capital Management's portfolio value fell 3.8% quarter-over-quarter to $1.31B.
Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.